0001209191-20-052461.txt : 20200930
0001209191-20-052461.hdr.sgml : 20200930
20200930163811
ACCESSION NUMBER: 0001209191-20-052461
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200928
FILED AS OF DATE: 20200930
DATE AS OF CHANGE: 20200930
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Campbell Bradley L
CENTRAL INDEX KEY: 0001400971
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 201212661
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 662-2000
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-28
0
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001400971
Campbell Bradley L
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY
NJ
08512
1
1
0
0
Chief Operating Officer
Common Stock
2020-09-28
4
M
0
24782
2.52
A
363546
D
Common Stock
2020-09-28
4
S
0
24782
13.8893
D
338764
D
Stock Options (right to buy)
2.52
2020-09-28
4
M
0
24782
0.00
D
2023-06-18
Common Stock
24782
60218
D
The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.69 to $14.01 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of the transaction date.
/s/ Christian Formica, Attorney-in-Fact
2020-09-30